Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fab'CD3-MORF2
- Development stage
- Preclinical
- Lead developer
- University of Utah
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Fab'CD3-MORF2 is a T-cell engaging component of the Multi-Antigen T-Cell Hybridizers (MATCH) system, a modular platform designed for the in situ assembly of bispecific T-cell engagers. It consists of an anti-CD3 antibody Fab' fragment covalently conjugated to a 25-base morpholino oligonucleotide (MORF2). The MATCH system functions through a pre-targeting strategy: a cancer-targeting Fab' fragment conjugated to a complementary oligonucleotide (MORF1) is first administered to bind to malignant cells. Subsequent administration of Fab'CD3-MORF2 allows the two components to hybridize on the cell surface, forming a functional bispecific complex. This complex recruits and activates T cells to induce targeted cytotoxicity against the cancer cells. This approach is being developed primarily for the treatment of multiple myeloma to overcome limitations of traditional bispecific antibodies, such as off-target toxicity and manufacturing complexity.
- Other names
- anti-CD3 Fab'-MORF2CD3-MORF2 conjugateCD-3-MORF2 conjugateCD 3-MORF2 conjugate
02
Targets
CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on Fab'CD3-MORF2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fab'CD3-MORF2.